Adverum Biotechnologies Inc (NASDAQ: ADVM) received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).  Adverum requested the FDA's feedback to align with the.